What is GHK-Cu peptide?

GHK-Cu — written variously as GHK Cu, GHKCu, or simply the copper peptide — is a naturally occurring complex of the tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys) bound to a divalent copper ion, Cu²⁺. It is one of the most studied peptide–metal complexes in the literature, and the reason is the copper: the peptide acts as a carrier that holds copper in a bound, bioavailable form.

Research use only. This page describes what GHK-Cu is and what published laboratory research has examined. It does not describe dosing or administration, is not guidance for use in humans or animals, and makes no therapeutic claims.

Where it came from

GHK was first isolated in the early 1970s from the albumin fraction of human plasma, during work investigating why plasma from younger donors behaved differently from older donors in liver-tissue culture. The active fraction turned out to be a three-amino-acid sequence, and the copper affinity was identified shortly afterwards. That origin matters for how the compound is framed: GHK-Cu was not designed as a drug candidate and then tested. It was found as an endogenous complex and then characterised, which is why the literature around it is unusually broad and unusually old compared with most research peptides.

Five decades of publication have produced a large but uneven body of work. Some of it is careful cell-culture and biochemical characterisation. Some of it is review writing that recycles the same primary sources. A researcher approaching GHK-Cu should expect to spend time separating the two.

The chemistry

GHK is a three-amino-acid sequence: glycine, histidine, lysine. On its own it is an unremarkable short peptide. What makes GHK-Cu distinct is that the histidine residue provides a binding site that chelates Cu²⁺ with high affinity, producing a stable complex with different properties from either component alone.

The complex occurs naturally in human plasma. Reported plasma concentrations decline substantially with age — an observation that prompted much of the early research interest, and one reason the compound is frequently discussed under the heading of ageing research rather than as a simple peptide.

The bound complex is also what gives GHK-Cu its most recognisable physical property. In solution it is a distinct blue, and the depth of that colour tracks the copper coordination. It is a useful informal check: a GHK-Cu solution that is colourless, or that has drifted toward green or brown, is telling you something about the state of the material. It is not a substitute for an assay, but it is the first thing an experienced hand looks at.

Why copper matters here

Copper is an essential trace element and a required cofactor for a number of enzymes, several of which are directly relevant to connective tissue:

• Lysyl oxidase, which cross-links collagen and elastin fibres
• Superoxide dismutase, part of the cellular antioxidant system
• Cytochrome c oxidase, in mitochondrial respiration

Free copper ions are reactive and tightly regulated in the body. A complex that carries copper in a bound state is therefore a useful experimental tool: it allows researchers to introduce copper into a system in a controlled form and observe what changes, rather than adding a free metal salt.

What the research examines

Most published work on GHK-Cu falls into three broad areas. All of it is laboratory research — cell culture and preclinical models — and findings differ considerably depending on concentration, exposure and the system used.

Extracellular matrix and collagen

The largest body of work concerns the extracellular matrix. In cultured fibroblast models, GHK-Cu has been examined in relation to collagen-related gene expression and to the behaviour of fibroblasts themselves — the cells responsible for producing and maintaining matrix proteins. Because copper is a cofactor for lysyl oxidase, which cross-links collagen, the peptide–copper pairing gives a mechanistic reason to expect matrix-related effects, and that is where the literature concentrates.

Skin research

Following from the matrix work, GHK-Cu appears extensively in skin research, which is why searches for the compound so often return cosmetic and dermatological sources. In-vitro studies have looked at gene-expression profiles in cultured skin cells, including genes associated with matrix remodelling and repair processes. It is worth being precise about what this means: these are cultured-cell observations, not clinical outcomes, and the presence of a compound in skin-research literature is not evidence of a cosmetic effect in people.

Hair research

In hair-research contexts, GHK-Cu has been examined in relation to dermal papilla cells in vitro — the cells at the base of the follicle involved in regulating the hair growth cycle. Again this is cell-culture work, and the relevant literature is exploratory rather than conclusive.

How GHK-Cu is actually used at the bench

Consumer writing about GHK-Cu rarely describes the experimental conditions, which is where most of the useful detail sits. A few practical points recur across the in-vitro literature.

Concentration ranges vary by orders of magnitude. Published cell-culture work spans from nanomolar to high-micromolar, and the direction of an observed effect is not always consistent across that range. Reporting a result without its concentration is close to meaningless, and comparing two papers that used different ranges is a common source of confusion in secondary write-ups.

The model system drives the result. Primary fibroblasts, immortalised keratinocyte lines, dermal papilla cells and full-thickness skin equivalents do not behave identically, and a finding in one is not evidence for another. Where a review says "GHK-Cu increases X", it is worth tracing back to which system produced that observation.

Copper controls matter. Because the complex delivers copper, a well-designed experiment separates the effect of the peptide–copper complex from the effect of copper itself, usually by running a copper-salt comparator and often a copper-free GHK arm as well. Studies without those arms cannot distinguish the two, which is a recurring limitation in the older literature.

Serum in the medium interferes. Copper binds avidly to serum albumin — that is how GHK-Cu was found in the first place — so serum-containing media complicate interpretation of any copper-carrier experiment. Serum-free or defined-media conditions are common in the more careful work for exactly this reason.

Copper peptides as a category

"Copper peptide" is used loosely, and the imprecision causes real confusion when comparing sources.

GHK-Cu is the copper peptide that the research literature overwhelmingly means. Other copper-binding peptide complexes exist and appear in cosmetic-chemistry contexts — AHK-Cu is the one most often encountered, and various proprietary copper tripeptide preparations are marketed under trade names rather than sequences. These are different molecules with different sequences and different published evidence, and a claim sourced from GHK-Cu work does not transfer to them.

When a source refers to "copper peptides" in the plural without naming a sequence, it is usually describing a formulation category rather than a defined compound. For research purposes the sequence is the compound, and anything without one cannot be sourced, verified or replicated.

GHK-Cu in serums and cosmetic formulations

A large share of the search interest in GHK-Cu comes from skincare, and it is worth stating plainly how that relates to research material, because the two are not interchangeable.

Cosmetic serums containing copper tripeptide are finished consumer products. They are formulated at low concentrations in a vehicle designed for topical application, are regulated as cosmetics, and are manufactured to that standard. Their concentration is generally not disclosed as a measured figure, and they are not accompanied by batch analytical documentation.

Research-grade GHK-Cu is a characterised reference compound, supplied with a batch Certificate of Analysis recording measured purity, and intended for in-vitro laboratory work. It is not formulated for application to skin, is not supplied for that purpose, and is not a cosmetic product.

We do not supply GHK-Cu for cosmetic or personal use, and material bought here should not be used that way. If you are looking for a skincare product, a regulated cosmetic from a cosmetics manufacturer is the correct thing to buy, and this is not it.

What "GHK-Cu benefits" writing gets wrong

Searches for the compound frequently return benefit lists. Reading them alongside the primary literature, three failure modes account for most of the distance between the two.

In-vitro findings are reported as outcomes. An observation that a gene's expression shifted in cultured fibroblasts is a mechanistic observation in a dish. It is not a demonstrated effect in a person, and the step between the two is the entire difficulty of translational research.

Concentration is dropped. As above: a result at 10 µM in serum-free medium says nothing about what a formulation containing an undisclosed amount does on intact skin, where the stratum corneum is a substantial barrier to a charged metal complex.

Reviews are cited as if they were experiments. Much of the secondary GHK-Cu literature consists of reviews citing other reviews. Tracing a claim to its original experimental source frequently shortens the list of things actually demonstrated.

None of this means the compound is uninteresting — it is one of the better-characterised peptide–metal complexes available, which is precisely why it is a useful research tool. It means the research question and the marketing claim are different things.

Stability, handling and why format matters

Copper peptide complexes are more sensitive than many short peptides, and for a reason specific to the chemistry: the property being studied depends on copper staying coordinated to the peptide. Conditions that disturb that coordination change what is in the vial.

pH governs the coordination directly. GHK-Cu is stable across a moderate near-neutral range and the complex is disturbed outside it, which is why buffer choice is not an incidental detail in a GHK-Cu protocol.

Oxidation and light matter more than for a plain peptide, because a redox-active metal is present. Copper cycling between oxidation states is the same chemistry that makes free copper reactive in biological systems.

Temperature applies as it does to any peptide in solution: cold storage slows degradation, and repeated warming and cooling is worse than continuous cold.

This is where supply format has a practical consequence. Lyophilised powder must be reconstituted by the end user, and reconstitution is the step where avoidable variability enters — water choice, added volume, mixing technique, and the delay before first use all differ between benches. Our GHK-Cu ships as a pre-mixed solution at a known concentration, prepared and documented under controlled conditions, which removes that step. For comparative work across batches this matters more than it might appear, since it is one fewer uncontrolled variable between the certificate and the experiment.

Reading a GHK-Cu certificate

A batch Certificate of Analysis is the only part of a supplier's claims that can be checked, so it is worth knowing what to look at.

• Measured purity, not a marketing figure. A COA should carry the value measured for that lot, not a generic "99%+" repeated across every batch.
• Batch identity that matches the vial. A certificate that cannot be tied to the material in front of you documents someone else's material.
• The analytical method. HPLC is the expected assay for purity; mass spectrometry confirms identity. A certificate with a number and no method is not evidence.
• A date. Peptide material is not indefinitely stable, and an undated certificate cannot tell you where a lot sits in its life.

Recent certificates are published in our COA library so the format can be reviewed before ordering rather than after.

Dosing and administration

We do not publish dosing, reconstitution-for-use or administration guidance for GHK-Cu, and that is deliberate rather than an omission. The material is supplied for in-vitro laboratory research and is not for human or veterinary use, so quantity guidance aimed at a person would be inconsistent with what is actually being sold.

Experimental concentrations for cell-culture work are specific to the model, the endpoint and the protocol, and belong in the primary literature rather than in a supplier's page.

What GHK-Cu is not

Because the compound circulates in popular skincare discussion, a few clarifications are useful for anyone approaching it as a research material:

• It is not an approved medicine in the UK or elsewhere, and is not supplied for human use.
• It is not the same as copper supplementation — the complex has properties distinct from copper salts, which is the entire point of studying it.
• Published in-vitro findings do not transfer straightforwardly to whole organisms. Concentration and delivery differ enormously between a culture dish and a living system.

How it is supplied

GHK-Cu is supplied as a pre-mixed 60mg solution — no reconstitution step required — with a batch-specific Certificate of Analysis recording identity and purity as measured by HPLC. Store refrigerated at 2–8°C.

It also appears as a component in two multi-compound sets: the Glow Stack, where it is combined with BPC-157 and TB-500, and the KLOW blend, which adds KPV. If you need to work out the concentration of a vial, the peptide calculator does the arithmetic.

For UK supply details — strengths, batch documentation, dispatch and trade volumes — see the GHK-Cu product page.